The sample size was calculated using a difference of proportions between two groups. A proportion difference of 17 points between the two groups with a confidence level of 95% and a power of 80% can be identified with an estimated sample size of 103 participants.
Study procedures and data collection
Sarcopenia (main variable) was assessed according to EWGSOP2 criteria. The SARC-F questionnaire was used both, to determine risk of developing and to assess the prevalence of sarcopenia. In order to confirm diagnosis and determine severity the following physical tests were assessed:
Hand-grip muscle strength, assessed using JAMAR Plus Digital Hand dynamometer (15, 16). The resident held the dynamometer in the hand, with the arm at a right angle and the elbow at the side of the body. Two maximal strength hand grips were obtained from both hands. The highest value from the dominant hand was used for analysis. The reliability of measuring handgrip strength with the Jamar dynamometer is high (ICC ¼ 0.94; p < .001) in a clinically compromised population of geriatric patients (15).
The amount of muscle was measured with a Tanita TBF-300 bioimpedance device (Tanita Institute, Tokyo, Japan). The residents climbed on top of the platform of the bioimpedance device and had to maintain the standing position without support for a few seconds. According to the literature, bioimpedance analysis (BIA) is the validated tool for measuring muscle mass in adults (17, 18). Through the appendicular skeletal muscle mass data, the skeletal muscle mass (SMM) was calculated using the formula of Jansen et al. (18):
SMM (kg) = [(Ht2/R* x 0.401) + (gender x 3.825) + (age x - 0.071)] + 5.102
*Ht is height in centimetres; R is BIA resistance in ohms. For gender, men = 1 and women = 0. Age is in years.
Finally, physical performance was assessed using the Gait Speed (19) from the Short Physical Performance Battery (SPPB) test. The individual is instructed to walk at a normal pace for 4 meters, including acceleration and deceleration distance, twice, with the use of a walking aid if necessary. The walk is timed and the shortest result is recorded. Gait speed of longer than 5 seconds to walk 4 metres (<0.8 m/s) suggests an increased risk of frailty and the need for further clinical review (20). Prata Martinez et al. 2015, demonstrated that the Gait Speed was a valid test with good reproducibility of physical performance in institutionalized older people (ICC=0.99; p=0.001) (20).
Participants with a final score of 4 or higher in SARC-F, were considered as sarcopenia risk. Regarding the physical tests, those individuals with sarcopenia risk and low muscle strength (<27 kg for men and <16 kg for women) were considered as probable sarcopenia. Those individuals who had probable sarcopenia and low muscle quantity (<20 kg for men and <15 kg for women) were reported as confirmed sarcopenia. In that latter cases, measures of low physical performance (≤0.8 m/s) were used to confirm severe sarcopenia (9, 7, 21). The category of total probable sarcopenia is composed by those subjects with probable sarcopenia and those with severe cognitive impairment, unable to perform physical tests and considered directly with low muscle strength (1).
Sociodemographic information such as age, sex, level of education, marital status, chronic diseases, smoking and drinking habits and hospitalisations, were obtained from the NH registers and checked with the NH professionals. The anthropometric variables were measured using a Seca 213 measuring device, the Tanita TBF-300. The total number of medications in daily use were registered, as well as the types of medications, according to the Anatomical Therapeutic Chemical classification system (22). Nutritional status was assessed using the Mini Nutritional Assessment (MNA) test (23). Continence status was reported using Section H of Minimum Data Set (MDS) version 3.0 (24). Functional capacity was measured using the modified Barthel Index, excluding continence items (25, 26). Cognitive status was assessed using the Pfeiffer Scale (27). Falls (number) over the last year were gained from NH records. Physical capacity was examined using the SPPB (28, 29), and frailty using the Clinical Frailty Scale (30, 31). Sedentary behaviour (SB) was assessed with the placement of the activPAL3TM activity monitor (PAL Technologies Ltd., Glasgow, UK), the device captured data continuously during both awake and sleep time, for 7 consecutive days (32, 33). The following variables were extracted: number of steps in a day, duration in minutes of SB periods, total time in SB (%), SB bouts, total time in standing position and walking in hours and transitions from sitting to standing during 24 hours.
The approximate time to complete the physical tests and questionnaires with each resident was 30 to 45 minutes. The research team that collected the data was trained on the use of all tools and tests. The team collecting data were assessed for reliability of the hand dynamometer, the SPPB (including Gait Speed), BIA and anthropometric measurements, with calculation of the Kappa index and the interclass correlation coefficient (ICC) of the data from 20 residents. The ICC results were higher than 0.75 in all physical tests. The results from these 20 residents were included in the total final sample of the study.